The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Trastuzumab MedChemExpress (MCE) Life Science Reagents

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Recent advances toward the development of Hsp90 C-terminal inhibitors - ScienceDirect

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Cancers, Free Full-Text

Soeun Park's research works Korea University, Seoul (KU) and other places

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer, Molecular Cancer

Transcriptomic analysis with HER2 and 611-CTF. (A) Venn diagram showing

Improved safety of NCT-50 compared with known Hsp90 inhibitors and

Recent advances toward the development of Hsp90 C-terminal inhibitors - ScienceDirect